Prof Chris Ormandy

Prof Chris Ormandy

Prof Chris Ormandy completed his undergraduate studies at the University of Sydney in 1984 and his PhD at the University of New South Wales in 1992. In 2003 Chris was the NHMRC CJ Martin Fellow at Institut Necker and Institut Pasteur Paris.  In 2006 he moved back to Australia and was appointed as a
Lab Head - Cancer Biology

Principal Research Fellow

Conjoint/Adjunct Role(s)

Conjoint Professor, St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney

Prof Chris Ormandy completed his undergraduate studies at the University of Sydney in 1984 and his PhD at the University of New South Wales in 1992.

In 2003 Chris was the NHMRC CJ Martin Fellow at Institut Necker and Institut Pasteur Paris.  In 2006 he moved back to Australia and was appointed as a senior scientist at the Kolling Institute, Royal North Shore Hospital.  In 2007 Chris joined the Garvan Institute of Medical research as a Research Group Leader.

Chris is currently President elect and board Member of the International Association for Breast Cancer Research, an Executive member of the Scientific Advisory Board of the National Breast Cancer Foundation Australia and a National Health and Medical Research Council Research Fellow.

Research Interests

The effect of the transcription factor Elf5 on progenitor cell fate decisions during mammary development, aspects of breast cancer phenotype such as sensitivity to estrogens, development of antiestrogen resistance, molecular subtype, epithelial to mesenchymal transition and metastatic activity
The relative contributions of oncogenic insult and cell of origin to tumour phenotype
The role of pathogen activated molecular pattern receptors in mammary development
The regulation of mammary development and function by prolactin

Awards and Honours

Senior Research Fellowship NHMRC Australia


1992 - PhD, University of New South Wales - Australia
1984 - BSc (Hons), University of Sydney - Australia

Selected Publications

Piggin CL, Roden DL, Gallego-Ortega D, Lee HJ, Oakes SR and Ormandy CJ. ELF5 isoform expression is tissue-specific and significantly altered in cancer. Breast Cancer Res 2016; 18:4.

Junankar S, Baker LA, Roden DL, Nair R, Elsworth B, Gallego-Ortega D, Lacaze P, Cazet A, Nikolic I, Teo WS, Yang J, McFarland A, Harvey K, Naylor MJ, Lakhani SR, Simpson PT, Raghavendra A, Saunus J, Madore J, Kaplan W, Ormandy C, Millar EK, O'Toole SA, Yun K and Swarbrick A. ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype. Nat Commun 2015; 6:6548.

Gallego-Ortega D, Ledger A, Roden D, Law AMK, Magenau A, Kikhtyak Z, Cho C, Allerdice SL, Lee HJ, Valdes-Mora F, Hermann D, Salomon R, Young AIJ, Lee BY, Sergio CM, Kaplan W, Piggin C, Conway JRW, Rabinovich B, Millar EKA, Oakes SR, Chtanova T, Swarbrick A, Naylor MJ, O'Toole SA, Green AR, Timpson P, Gee JMW, Ellis I, Clark SJ and Ormandy CJ. ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr-1+CD11b+ myeloid derived suppressor cells. PloS Biol 2015; 13:e1002330.

Oakes SR, Gallego-Ortega D and Ormandy CJ. The mammary cellular hierarchy and breast cancer. Cell Mol Life Sci 2014; 71:4301-4324.

Gallego-Ortega D, Oakes SR and Ormandy CJ. Elf5, normal mammary development, and the heterogeneous phenotypes of breast cancer. Breast Cancer Management - Future Medicine 2013; 2:489-498.

Lee HJ, Gallego-Ortega D, Ledger A, Schramek D, Joshi P, Szwarc MM, Cho C, Lydon JP, Khokka R, Penninger J and Ormandy CJ. Progesterone drives mammary secretory differentiation via RankL-induction of Elf5 in luminal progenitor cells. Development 2013; 140:1397-1401.

Lee HJ and Ormandy CJ. Elf5, hormones and cell fate. Trends Endocrin Met 2012; 23:292-298.

Kalyuga M, Gallego-Ortega D, Lee H, Roden D, Cowley M, Caldon CE, Stone A, Allerdice S, Valdes-Mora F, Launchbury R, Statham A, Armstrong N, Alles C, Young A, Egger A, Au W, Piggin C, Evans C, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll J and Ormandy CJ. ELF5 suppresses estrogen sensitivity and underpins the acquisition of anitestrogen resistance in luminal breast cancer. PloS Biol 2012; 10:e1001461.

Lee HJ, Hinshelwood RA, Bouras T, Gallego-Ortega D, Valdes-Mora F, Blazek K, Visvader JE, Clark SJ and Ormandy CJ. Lineage specific methylation of the Elf5 promoter in mammary epithelial cells. Stem Cells 2011; 29:1611-1619.

Alles CM, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA and Ormandy CJ. Meta-analysis and gene set enrichment relative to ER status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One 2009; 4:e4710.

Oakes SR, Naylor MJ, Asselin-Labat ML, Blazek K, Gardiner-Garden M, Hilton HN, Kazlauskas M, Pritchard M, Chodosh LA, Pfeffer PL, Lindeman GJ, Visvader J and Ormandy CJ. The Ets transcription factor Elf5 is essential for specifying mammary alveolar cell fate. Genes Dev 2008; 22:581-586.

Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE and Ormandy CJ. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 2007; 26:543-553.

Harris J, Stanford PM, Sutherland K, Oakes SR, Naylor MJ, Robertson FG, Blazek KD, Kazlauskas M, Hilton HN, Wittlin S, Alexander WS, Lindeman GJ, Visvader JE and Ormandy CJ. Socs2 and Elf5 mediate prolactine-induced mammary gland development. Mol Endocrinol 2006; 20:1177-1187.

Naylor MJ, Ginsburg E, Iismaa TP, Vonderhaar BK, Wynick D and Ormandy CJ. The neuropeptide galanin augments lobuloalveolar development. J Biol Chem 2003; 278:29145-29152.

Brisken C, Kaur S, Chavarria TE, Binart N, Sutherland RL, Weinberg RA, Kelly PA and Ormandy CJ. Prolactin controls mammary gland development via direct and indirect mechanisms. Dev Biol 1999; 210:96-106.

Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, Edery M, Brousse N, Babinet C, Binart N and Kelly PA. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 1997; 11:167-178.